HBW Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

FDA appropriations

This article was originally published in The Rose Sheet

Executive Summary

Center for Food Safety and Applied Nutrition Adverse Events Reporting System would receive $7.6 mil. in FY 2003 funding under Senate Agriculture Appropriations bill, which unanimously passed out of committee July 25. CAERS funding represents $2 mil. more than budget request. Measure also provides $2 mil. for botanical research carried out by FDA, U-Miss. center. Bill calls for $149.3 mil. in funding for CFSAN and total FDA funding of $1.39 bil., which is $23.4 mil. more than budget request. Full Senate vote has yet to be scheduled...

You may also be interested in...



CFSAN AER system

Center for Food Safety & Applied Nutrition expects to have new adverse events reporting system for cosmetics, food and color additives and dietary supplements in place by May 2003, FDA reports. CFSAN Adverse Event Reporting System (CAER), which is undergoing pilot testing, will replace existing three AER systems. Older versions will remain in place until new system is implemented, agency says. Beginning on or after Sept. 16, CFSAN will send letters to companies notifying them when an AER involving one of their products has been received. Under Senate Agriculture Appropriations bill, CFSAN's AER system would receive $7.6 mil. in FY 2003 funding (1"The Rose Sheet" Aug. 5, 2002, In Brief)...

Deal Watch: AbbVie Teams With MedinCell On Long-Acting Injectables

Collaboration Edition: Including deals involving Evotec/Variant, Sanofi/IGM/Nurix, ABVC/OncoX and Harmony/Bioprojet, along with tech transfer agreements and deals in brief.

GE HealthCare Launches AI-Powered Voluson Ultrasound For Women’s Health

Voluson Signature 20 and 18 ultrasound provides clinicians with workflow efficiencies in detecting female reproductive health problems, especially those related to pregnancy.

Latest Headlines
See All
UsernamePublicRestriction

Register

RS010498

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel